CTOs on the Move

Sentien Biotechnologies Inc

www.sentienbiotech.com

 
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel approaches to cell therapy. Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Sentien Biotechnologies Inc raised $12M on 04/04/2017

Similar Companies

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.

Neova Technologies

Neova Technologies Inc. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.

Sigma-Tau Pharmaceuticals

Sigma-Tau Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GT Biopharma

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin`s lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology.